



STRATEGIES TO ACHIEVE LONG-TERM SUSTAINABILITY

In this article, Peter Soelkner and Thomas Otto, both Managing Directors at Vetter, discuss how the pharmaceutical service provider focuses on sustainability.

The history of Vetter started with a simple pharmacy in a late Gothic, half-timbered house in Ravensburg city centre in Germany, which is still there today and serves as a reminder of the first entrepreneurial steps taken by founder Helmut Vetter in the 1950s.

The pharmaceutical service provider produces injectable drugs for its customers in the pharmaceutical and biotech industries that are vital for patients around the world. Among them are medications for cancer, multiple sclerosis and rheumatoid arthritis, as well as treatments for rare diseases. Vetter employs 5,500 staff in Ravensburg and Langenargen in Germany, as well as at sites in Austria, the US and Asia.

The company has remained down-to-earth and is proud of its roots in the region, which have enabled it to achieve significant growth. Since its foundation, Vetter has consistently pursued its path as a family-owned business that focuses its activities on the well-being of patients and takes a long-term view. The topic of sustainability

plays a central role for the organisation on many levels – it aims to improve the quality of life of millions of patients worldwide in a sustainable manner. At Vetter, responsibility towards both patients and society are inseparably linked.

COMMITMENT TO CLIMATE PROTECTION

The understanding that global carbon dioxide emissions must be sharply reduced has continued to grow worldwide. Vetter recognised this need early on and has been using green technologies for many years, while also making continuous investments in climate protection. For example, since 2014, all Vetter's German sites have been operating with green power from hydroelectric plants. The company reached another milestone last year when it achieved carbon dioxide neutrality in all its corporate activities at every German site, and has since gone on to achieve carbon neutrality worldwide (Figure 1).

In view of the high quality standards and numerous regulatory requirements in the pharmaceutical industry, residual emissions cannot be completely avoided. This makes it all the more important for companies to compensate for this by supporting climate protection projects. These projects are subject to strict criteria – for example, the



Peter Soelkner
Managing Director



Thomas Otto
Managing Director

Vetter Pharma International GmbH
Eywiesenstraße 5
88212 Ravensburg
Germany

www.vetter-pharma.com

“Since 2014, all Vetter's German sites have been operating with green power from hydroelectric plants.”



Figure 1: All Vetter sites around the world are carbon dioxide neutral.

“Vetter has its environmental, energy management and occupational safety activities certified on a regular basis.”

exclusive production of renewable energies, including wind, solar or biogas. Vetter also has its environmental, energy management and occupational safety activities certified on a regular basis.

The Center for Visual Inspection and Logistics in Ravensburg (Figure 2) is a good example of Vetter’s sustainability strategy. It combines the operation of an environmentally friendly biogas block-type thermal power station with the use of geothermal energy and surplus energy, as well as photovoltaic systems. In this way, a sustainable energy concept is consistently implemented. The site has already won a prestigious international industry award for its efforts as a “factory of the future”.

FOCUS ON SUSTAINABLE MOBILITY

But sustainability initiatives don’t always have to be high-tech. Vetter is also breaking new ground when it comes to healthy mobility and creating a greener region. For example, the company offers its staff members a leasing model for e-bikes and bicycles. Vetter also encourages its workforce to collect green kilometres by participating in initiatives such as “Green Ways to Work”. The company recognises that cycling is a great way to do something good for both yourself and the environment at the same time – and it is pleased with the enthusiasm its employees have shown for the campaigns and their many benefits.

Figure 2: The Ravensburg Vetter West site honoured as a “factory of the future”.

For cyclists who have worked up a sweat on their way to work, showers are available in the Vetter buildings. In addition, the company has invested in cycling infrastructure such as modern bicycle parking facilities with battery charging stations for e-bikes and on-site kits for minor repairs (Figure 3) – all intended to make switching to bicycles even more attractive.

Baden-Wuerttemberg’s Minister of Transport Winfried Hermann has expressed open support for the project, stating that “The efforts of sustainability have been advanced here with commitment and initiative, which is important for the sustainable development of economic and living spaces.” Staff members can use electric bicycles between the individual sites – a model project in co-operation with Technische Werke Schussental.



Figure 3: Vetter has invested in modern bicycle parking facilities with battery charging stations and repair kits.

"The company is constantly working to keep its ecological footprint as small as possible."

CULTURE OF RESPONSIBILITY

Companies have many ways to act in a sustainable manner and make sustainability a significant part of their corporate philosophy. High standards in the areas of environment and energy use, as well as health and occupational safety, are just as much a part of Vetter as social commitment, diversity and education. The company is constantly working to keep its ecological footprint as small as possible. As a family business with a long-term focus, Vetter sees this as an important component of its social responsibility – not just for today but also for future generations.

ABOUT THE COMPANY

Vetter is a family-owned, leading global CDMO with production facilities in Germany, Austria and the US. Currently employing more than 5,500 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers, both large and small. Vetter's services range from early-stage development support, including clinical manufacturing, to commercial supply and numerous packaging solutions for vials,

syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety and convenience, as well as enhanced compliance. Great importance is also given to social responsibility, including environmental protection and sustainability.

ABOUT THE AUTHORS

Peter Soelkner has been a Managing Director of Vetter since June 2008. He graduated from the University of Dortmund (Germany) in 1992 with a degree in chemical engineering and earned an MBA from Columbia University (NY, US) in 2001. Before joining Vetter, he held positions in Germany and North America at Sartorius AG and Sartorius North America Inc in research and development, marketing and key account management, as well as general management roles.

Thomas Otto assumed the position of Managing Director at Vetter in December 2002. He began his employment at Vetter in the early 1990s as a project engineer. From 1995 to 1999, he was Manager of Packaging Materials Development and, from 2000 to 2002, he headed the R&D department. Mr Otto graduated with an engineering degree in packaging technology and print processing in 1990.

E&L EUROPE
Extractables & Leachables
delivering pharmaceuticals safely

HYBRID EVENT


**17-18 NOVEMBER 2021
IN BRUSSELS & ONLINE**

Europe's leading conference dedicated to extractables & leachables

"The place to be for the E&L community" - Agilent

USE CODE ELEU21ODD
SAVE 10%!

→ **FIND OUT MORE AT [EANDL-CONFERENCE.COM/EUROPE](https://eandl-conference.com/europe)**



Comprehensive support for your injectables

Meet our experts
@CPhI Worldwide 2021
Milan · Nov 9-11
on-site at booth 2D11

For over 40 years, Vetter has been a trusted partner in injectables manufacturing for pharmaceutical and biotech companies around the world. Our deep expertise enables us to integrate with your team to design and implement a personalized plan for success in a shifting global marketplace. Our strategic partnership includes:

- Customized clinical and commercial manufacturing services for your product throughout its lifecycle
- Deep and comprehensive technical, analytical, and regulatory subject matter expertise
- Proven manufacturing processes that are flexible, efficient, and scalable
- Filling and packaging capabilities that utilize the latest technology to meet international market demands



www.vetter-pharma.com



VETTER
Answers that work